Preferences for a Clostridioides difficile vaccine among adults in the United States
OOP cost, improvements in vaccine effectiveness, and reduction in CDI severity were highly influential to vaccine selection. Most adults aged ≥50 years were receptive to a C.diff vaccine, especially with little-to-no OOP cost, suggesting that mandating insurance coverage of vaccination with no copayment may increase uptake. The limited awareness about C.diff among adults presents an opportunity for healthcare providers to educate their patients about CDI prevention.
Authors
- Jeffrey Vietri (ORCID: https://orcid.org/0000-0002-5610-3098)
- Kathleen Marie Beusterien (ORCID: https://orcid.org/0000-0001-7786-5422)
- Martine C. Maculaitis (ORCID: https://orcid.org/0000-0001-8388-5315)
- Holly Yu (ORCID: https://orcid.org/0000-0001-8625-4201)
- Lewis Kopenhafer
- Joseph C. Cappelleri (ORCID: https://orcid.org/0000-0001-9586-0748)
Institutions
- Oracle (United States) (US)
- Pfizer (United States) (US)
Publication Details
- Journal
- Vaccine
- Published
- 2024-08-31
- DOI
- https://doi.org/10.1016/j.vaccine.2024.126261
- Citations
- 1
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Pfizer